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e Estatística)). RESULTS: Our computed values vary across
countries and across time. The average STP rate for the 167
countries in the sample is 6.8% and the standard deviation 3.9%.
The ﬁgures ranged from -6.8% for Equatorial Guinea to 18.6%
for Armenia. For Brazil, STP rates display a decreasing proﬁle
across time, with an average rate of 4.7%. Computed ﬁgures
vary from 3.6% to 5.5%. CONCLUSIONS: The standardisation
of the use and estimation of discount rates in the economic
evaluation of health care programmes (EEHCP) is a core quest,
especially with the increase of EEHCP as a tool for decision
making. The variation of STR rate results indicate the need for
country-speciﬁc discount rate estimation.
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OBJECTIVES: This study aims to compare the impact of two
different sources of resource use, self-report versus routine
registrations, on incremental cost-effectiveness ratios (ICERs).
METHODS: Data were obtained from a cost-effectiveness study
performed alongside a two-year randomized controlled trial
evaluating the effect of an INTERdisciplinary COMmunity-
based management program (INTERCOM) for patients with
chronic obstructive pulmonary disease (COPD). The program
consisted of exercise training, nutritional therapy, education and
smoking cessation support offered by community-based physio-
therapists and dieticians and hospital-based respiratory nurses.
Data on caregiver visits, hospitalizations, diet nutrition, devices,
(un)paid help, travel expenses and time lost from paid work over
the two-year period were collected using a cost booklet. In addi-
tion, data on hospital admissions and outpatient visits, visits to
the physiotherapist, dietician or respiratory nurse, diet nutrition
and outpatient medication were obtained from hospital- and
billing records and local pharmacies. The cost per QALY was
calculated in two ways, using data from the cost booklet or
registrations. RESULTS: In total 175 patients were included in
the study. Agreement between self-report and registrations was
good for hospitalizations (r = 0.96), diet nutrition (r = 0.91) and
physiotherapist visits (r = 0.89), but above 0.58 for all other
types of care. The total cost difference between the registrations
and the cost booklet was €464 with the highest difference for
hospitalizations 386 euro. Based on the cost booklet the cost
difference between the treatment group and usual care was
€2,444 (95% CI: -819–5,950), which resulted in an ICER of
€29,100/QALY. For the registrations, the results were €2,498
(95% CI: -88–6,084) and €29,390/QALY, respectively. No dif-
ferences were found in the cost-effectiveness planes and the
acceptability curves between the two methods. CONCLUSIONS:
This study showed that the use of self-reported data or data from
routine registrations effected within group costs, but not between
group costs or the ICERs.
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OBJECTIVES: To assess trends in the prevalence and type of
economic analysis alongside randomized controlled trials (piggy-
back trials) published between 1997 and 2007. METHODS: We
searched Medline for a total number of Randomized Controlled
Trials published between 1997 and 2007. Economic studies
alongside RCTs were searched by using the additional MeSH
terms, costs and cost analysis. The abstract of each retrieved,
English-language study was reviewed and economic studies
alongside RCTs were identiﬁed. Included studies were catego-
rized further by the type of analysis, perspective and interven-
tions. RESULTS: Our search identiﬁed a total of 131,454 RCTs
and 2820 economic analysis alongside RCTs. A total of 2077
studies met inclusion criteria and further analyzed. Only 1.58%
of published RCTs included economic analysis. The prevalence
of economic studies alongside RCTs as a proportion of RCTs was
fairly constant over 1997–2007, except for the year 2000 where
a higher prevalence (2.07%) was observed. Cost effectiveness
analyses was most frequently reported (46.12%) followed by
cost minimization (2.74%), cost beneﬁt (2.6%) and cost utility
(1.4%). More than one type of analyses was reported in 3.17%
of studies. The remaining 44.05 % of studies were either cost
analysis or cost-consequence analysis or were unclear. The inter-
ventions considered in the trials were drugs (36.3%), devices or
surgical techniques (22.14%), behavioral studies (4.91%), pre-
ventive studies (3.9%), and others (30.38%).The perspective of
economic analysis was stated in only 8.32% of studies. Federal,
hospital, patient, payer, societal and state agency perspective
were reported by 1.2%, 1.3%, 0.38%, 1.05%, 2.84%, and
0.52% of studies respectively. CONCLUSIONS: We observed an
increase in the prevalence of economic analysis in randomized
controlled trials than earlier years. Also, the number of drug
trials and devices and surgical technique trials has increased from
before 1997. The reporting of trial perspective was found very
low. This could be because of external-validity problems with
piggy-back trials.”
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OBJECTIVES: Economic evaluation of health technologies is
increasingly used to inform decision-making in health policy. It is
standard practice in cost-effectiveness analysis to discount future
health beneﬁts at the same rate as costs and to apply a baseline
rate between three and ﬁve percent a year. Public health advo-
cates of prevention programmes often argue that devaluing
future health gains through discounting is inappropriate. The
purpose of this paper is to re-examine the arguments of the social
time preference approach for discounting health beneﬁts at some
positive rate and at the same rate as the costs. METHODS: The
paper is based on a systematic review of the literature on the
foundations of discounting in the economic evaluation of health
care programmes published during the time period 1989–2008.
RESULTS: According to the social time preference approach the
main arguments for discounting are the individual’s uncertainty
about the returns of investment, diminishing marginal utility and
pure time preference. None of these arguments convincingly
supports a positive and distinct discount rate for health gains.
Particularly the argument of pure time preference is challenged,
e.g. by the problem of myopia, the divergence between private
and collective decision behaviour, and the neglect of distribu-
tional concerns of public health policy. A more fundamental
weakness of the welfaristic framework is that is does not provide
an appropriate conceptual basis for dealing with the question
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of intergenerational discounting. CONCLUSIONS: Cost-
effectiveness analysis will increasingly play an informative role in
policy analysis of public health interventions even though it is not
clear what discount rate is appropriate in each case. However,
especially for programmes characterized by long-term dimin-
ished risk of disease, death or sequel avoided, possibility of
disease eradication, and substantial intergenerational impact,
there are no convincing arguments favouring the use of subjective
time preferences when setting ofﬁcial discount rates for applica-
tion in social project evaluation.
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OBJECTIVES: In cost-effectiveness analysis, we aim to account
for all future costs and beneﬁts for all patients who are currently
eligible for a new health technology and who will become eligible
in the future. METHODS: We adapt the fundamental concept
from epidemiology of the incidence and prevalence of a disease to
cost-effectiveness analysis. We deﬁne the prevalent cohort as
those patients eligible to switch from the comparator to the new
technology at the time the new technology is introduced. Next,
we introduce the concept of multiple future incident cohorts. The
incident cohort starting t years in the future consists of those
patients who ﬁrst become eligible for the new technology t years
in the future. Currently cost-effectiveness analyses worldwide
consider only either the prevalent cohort, the incident cohort in
only the ﬁrst year, or a mixture of the two. RESULTS: On
average, patients in the prevalent cohort are older and at a more
advanced stage of illness than patients in the incident cohort. If
the cost and beneﬁt discount rates differ, we show mathemati-
cally that the cost-effectiveness of all technologies will be sub-
stantially affected by our method. Otherwise, the incremental
cost-effectiveness ratio will not change for acute conditions, but
may change substantially for chronic conditions, particularly for
chronic progressive conditions. CONCLUSIONS: We suggest
that analyses capture the costs and beneﬁts arising from the
prevalent cohort and all future incident cohorts. If our method
had been used in the past, some health technologies would have
appeared substantially more cost-effective, others substantially
less cost-effective. If possible, parameter values (e.g. average age,
disease severity) for both the incident and prevalent cohorts
should be obtained from the literature. Otherwise, we describe
how such parameters can be estimated.
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OBJECTIVES: Economic evaluation(EE) incorporate some
degree of uncertainty and variability that arises in a number of
ways. Uncertainty represents lack of perfect knowledge on the
part of the analyst and may be reduced by further measurement
and variability represents heterogeneity or diversity in a popula-
tion that is irreducible by additional measurements (Spanish-
guidelines proposal). This paper tries to shed light on the need to
separate uncertainty and variability in the EE. METHODS: We
propose the Probabilistic Sensitivity Analysis (PSA) as an efﬁcient
methodology to treat uncertainty associated to the model
“inputs”. In PSA, a single variable (or subset of variables) is
allowed to vary within its speciﬁed probability distribution, and
repeat-run sampling-based simulations are performed to produce
a weighted distribution of output estimates. It is proposed a
bayesian estimation of the results of a target parameter
[q|Data] = [Data|q]*[q]/[Data] subsequently to PSA as an
improvement of the method. We propose calculating the Baye-
sian interval of probability (BIP) [q|a,b] of the costs associated
with treatment during the PSA calculations(it has been assumed
that [q|a,b] ª Beta(a,b)[UNKNOWN NODETYPE 9]), deﬁned as
those that have an interval probability “high” to contain the
parameter; equivalent to frequentist conﬁdence interval
P(qmin  q  qmax) = 1 - a[UNKNOWN NODETYPE 9],
using Markov Chains Monte-Carlo but measured as a probabil-
ity not as conﬁdence (a based). RESULTS: We have studied
different scripts using WinBugs and FirstBayes packages for cal-
culating of the estimated costs BIP in a PSA, simulating highly
skewed distributions of costs. The separation of uncertainty and
variability can affect the study results and policy-making deci-
sions in a non-negligible manner and the best methodology to
treat the uncertainty is PSA. CONCLUSIONS: Furthermore this
paper is a brief introduction to the decision models, their relation
to Bayesian decision theory, and the tools typically used to
describe the uncertainties involved presenting an improvement in
the PSA using a BIP of the estimated parameters as a robust
method.
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Decision-making about resource allocation for guideline imple-
mentation to change clinical practice is inevitably undertaken in
a context of uncertainty surrounding the cost-effectiveness of
both clinical guidelines and implementation strategies. Recently,
a model has been developed in which monetary values are
assigned to health outcomes and economic evidence on guide-
lines and strategies is combined with information on clinical
practice to determine the scope of cost-effective guideline imple-
mentation. Adopting a net beneﬁt approach, the model over-
comes problems with the use of combined ratio statistics when
analyzing decision uncertainty concerning clinical practice
change. OBJECTIVES: The stochastic application of the model is
demonstrated for informing decision-making about the adoption
of an audit and feedback strategy for implementing a guideline
recommending intensive blood glucose control in type 2 diabetes
in primary care in The Netherlands. METHODS: An integrated
Bayesian approach to decision modelling and evidence synthesis
is adopted using Markov Chain Monte Carlo simulation in
WinBUGs. Data on model parameters is gathered from various
sources, with the effectiveness of audit and feedback being
estimated using a pooled, random effects meta-analysis model.
Decision uncertainty is illustrated using cost-effectiveness accept-
ability curves (CEACs) and frontier (CEAF). RESULTS: Deci-
sions about whether to adopt the guidance on blood glucose
control and whether to adopt audit and feedback for its imple-
mentation alter over the range of maximum values that decision-
makers are willing to pay for health gain. Through
simultaneously incorporating uncertain economic evidence on
both guidance and implementation strategy, the CEACs and
CEAF show an increase in decision uncertainty concerning guide-
line implementation. CONCLUSIONS: The stochastic applica-
tion in diabetes care demonstrates that the model provides a
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